

NATCO Pharma Ltd

NATCO House

Road No.2, Banjara Hills

Hyderabad-500 034, India

Hyderabad, India, February 12th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for third quarter of financial year 2026.

NATCO records ₹705.4 Crore consolidated revenue and ₹151.3 Crore of profit after tax for Q3FY26

NATCO recorded consolidated total revenue of INR 705.4 Crore for the quarter ended on 31st December 2025 as against INR 651.1 crore as of 31st December 2024. EBITDA (including other income) for the quarter was at INR 216.8 Crore with margins at 30.7%. The net profit for the period, on a consolidated basis was INR 151.3 Crore.

Revenue from associated company, Adcock Ingram holdings Ltd., South Africa, for the first half of their financial year ending Dec 31st, 2025, was INR 2,464 Crore at a profit after tax of INR 198 Crore. For NATCO, the profit pick-up for the period from 10th November to 31st December 2025 at 35.75% amounts to INR 29.65 Crore. After a one-time/period amortisation of INR 18.75 Crore, the associate profit reflection in NATCO's financials amounts to INR 10.90 Crore.

The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q3FY26.

Segmental Revenue Split (INR Crore)

Business Segments	Q3FY26	Q2FY26	Q3FY25
Active Pharmaceutical Ingredients (API)	64.3	53.9	66.6
Domestic Formulations	119.8	105.4	96.1
Formulations export (Incl. profit share and subs)	421.4	1,147.0	285.8
Crop Health Sciences (CHS)	28.5	52.4	15.1
Other operating and non-operating income	71.3	104.3	187.5
Total	705.4	1,463.0	651.1

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Earnings Call Details:

- *Date: 12th February 2026, Thursday*
- *Time: 4 PM IST*
- **Dial-in-Numbers:**
 - *India: (+91 22) 62801222 / 71158123*
 - *US: 18667462133*
 - *UK: 08081011573*
 - *Singapore: 8001012045*

For further information please contact:

Rajeev Menon, Investor Relations

ir@natcopharma.co.in/r.menon@natcopharma.co.in

Rajesh Chebiyam, EVP – CHS

rajesh.chebiyam@natcopharma.co.in